NACIMBIO, a Russian pharmaceutical holding company established by Rostec State Corporation in 2013, develops and produces immunobiological products critical to national security. It includes leading research and production enterprises—NPO Mikrogen and FORT. The holding specializes in the development and supply of vaccines and toxoids for the National Immunization Schedule, as well as blood products, bacteriophages, allergens, and botulinum toxin type A. The company’s portfolio includes over 150 products.